Mereo BioPharma reports FY24 EPS (6c), consensus (5c)

Reports revenue $0 vs. $10M last year. “2024 was a year of focused execution and strategic advancement at Mereo, driving our lead programs closer to key milestones,” said Dr. Denise Scots-Knight, CEO. “The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta is set to read out at the upcoming second interim analysis mid-year or at the final analysis during the fourth quarter of 2025. This could set the stage for us, alongside our partner Ultragenyx, to file for regulatory approvals in the U.S. and EU. Our European pre-commercial activities are ongoing, where we are focused on laying the foundation for a successful and efficient commercial launch, following potential regulatory approval. On alvelestat, the recent receipt of European Orphan Designation and the Phase 3 readiness activities have been highly supportive for our ongoing partnering process. With a strong financial position, we look forward to a transformative 2025, focused on bringing life-changing therapies to patients with rare diseases.”